Compare AbbVie Inc (ABBV) vs Nucor Corporation (NUE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Nucor Corporation — how do they compare? AbbVie Inc trades at $252.67 (market cap $449.91B), while Nucor Corporation trades at $226.7 (market cap $51.79B). The key difference: AbbVie Inc is far larger — about 8.7× Nucor Corporation's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | NUE | |
|---|---|---|
Market Cap | $449.91B | $51.79B |
Sector | Health | Basic Materials |
52-Week High | $261.07 | $266.35 |
52-Week Low | $184.85 | $131.78 |
Enterprise Value | $513.38B | $56.44B |
Dividend Yield | 2.72% | 0.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with a bullish technical outlook supported by moving averages and strong support at $248. The company reported revenue of $61.16B in 2025, with EPS beats in recent quarters, though net income margin has trended down to 5.79%. Key growth drivers Skyrizi and Rinvoq are offsetting Humira declines, with positive clinical updates like the Phase 2 ELAHERE data at SGO 2026.
The stock offers a compelling buy case with a consensus price target of $266.33 (5.4% upside) and strong analyst support (68% buy ratings). However, risks include patent cliffs in the 2030s, high debt levels, and margin pressure. Dividend growth is recovering, supporting income investors, but execution on pipeline assets remains critical for sustained expansion.
Nucor (NUE) trades at $227.42, up 3.02% over the past day, with a bearish technical signal despite recent earnings beats. The stock shows mixed sentiment with 59% analyst buy ratings but faces declining revenue and net income from 2022 peaks. Recent developments include a joint venture to support AI power infrastructure and a consistent dividend history, with Q2 2026 EPS guidance projecting growth.
Outlook remains cautiously optimistic due to strong analyst targets averaging $260.75 and operational expansions, though risks include steel demand volatility and compressed profit margins. The stock's valuation at a P/E of 22.21 appears reasonable if earnings rebound as projected in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →
